Jefferies downgraded Inspire Medical (INSP) to Hold from Buy with a price target of $85, down from $160. The firm’s U.S. sleep survey and doctor checks show ongoing headwinds from weight loss drug uptake, competitor share gains, and “muted” expectations on Inspire 5-related volume growth. Jefferies no longer has confidence in Inspire’s ability to accelerate sales growth. As such, it no longer expects multiple expansion to drive the shares higher.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical price target lowered to $90 from $125 at Truist
- Inspire Medical price target lowered to $150 from $180 at RBC Capital
- Inspire Medical Systems Unveils Positive Data for Inspire V
- Inspire Medical publishes Inspire V data at ISSS/AAO-HNS meetings
- Inspire Medical downgraded to Neutral from Buy at UBS